info@seagull-health.com
SeagullHealth
search
bictegravir/emtricitabine/tenofovir alafenamide(Biktarvy)
Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Xagrid(bictegravir/emtricitabine/tenofovir alafenamide) Instructions:Uses,Dosage, Side Effects
BIKTARVY contains three active components: bictegravir, which is an integrase strand transfer inhibitor (INSTI); emtricitabine, a nucleoside reverse transcriptase inhibitor (NRTI); and tenofovir alafenamide (TAF), another NRTI. It is formulated as an oral tablet and serves as a complete regimen, meaning it does not require additional antiretroviral agents.
The medication is designed to suppress HIV-1 replication and is available in different strengths to accommodate various patient weights, starting from 14 kg. It was initially approved in the U.S. in 2018 and is intended for long-term management of HIV-1, helping to reduce viral load and support immune function.
Treatment-naïve adults and pediatric patients (≥14 kg) with HIV-1.
Virologically suppressed patients switching from a stable antiretroviral regimen with no known resistance to BIC or tenofovir.
Patients with antiretroviral treatment history who are not virologically suppressed, provided there are no known resistance-associated substitutions to INSTIs, FTC, or tenofovir.
Adults and pediatric patients ≥25 kg: one 50/200/25 mg tablet once daily.
- bictegravir/emtricitabine/tenofovir alafenamide Indications
- bictegravir/emtricitabine/tenofovir alafenamide Dosage
- bictegravir/emtricitabine/tenofovir alafenamide Price
- bictegravir/emtricitabine/tenofovir alafenamide Treatment Effects
- bictegravir/emtricitabine/tenofovir alafenamide Precautions
- bictegravir/emtricitabine/tenofovir alafenamide Side Effects
- Core products
- Antitumor drugs
- General drug
- Antiviral drugs
- Biological agents
- haiousales@gmail.com
